What Is Gossamer Bio, Inc. (GOSS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Gossamer Bio, Inc.'s intrinsic value is estimated at a composite fair value of $0.36. At a current market price of $0.16, 6 of 8 active valuation models identify upside potential, projecting an average implied return of +120.1%. Notably, Regime Cross sees the most upside at +271.4% (fair value: $0.60), while Dynamic NAV is the most conservative at -70.8% ($0.05). The spread between these extremes — +342.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About GOSS?
8 of 13 models are currently active for GOSS. Of these, 7 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates GOSS's intrinsic value at $0.20, implying +25.7% upside from the current price. See which stocks rank higher →
How Does GOSS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, GOSS ranks #221 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Gossamer Bio, Inc.'s positioning within the Pharmaceutical Preparations segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is GOSS a Value Trap?
CirclFi's Value Trap algorithm assigns GOSS a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Gossamer Bio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Gossamer Bio, Inc. earns a quality score of 4.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +342.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GOSS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GOSS's 8 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad